Literature DB >> 2082334

Pediatric thyroid cancer.

A E Sierk1, F B Askin, R L Reddick, C G Thomas.   

Abstract

A review was undertaken of the clinical, gross, and microscopic features of thyroid carcinoma in all patients younger than 21 years of age seen at North Carolina Memorial Hospital from 1952 to 1987 (N = 32). These patients had papillary carcinoma, well-differentiated follicular carcinoma with Hürthle cell change, medullary carcinoma, and an unclassifiable aggressive malignancy. In spite of the presence of lymph node metastases at diagnosis in more half the patients with papillary carcinoma, the prognosis of pediatric papillary thyroid carcinoma appears to be excellent with treatment by surgical debulking and hormonal thyroid suppression. Flow cytometric study of 26 cases showed tumor aneuploidy in 8 of 21 papillary carcinomas and 2 of 3 follicular carcinomas. Aneuploidy did not, however, correlate with clinical outcome in this group of pediatric patients, who were followed for 1 to 29 years. Analysis of multiple tissue blocks of tumor does appear to increase the probability of identifying aneuploid populations.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2082334     DOI: 10.3109/15513819009064723

Source DB:  PubMed          Journal:  Pediatr Pathol        ISSN: 0277-0938


  4 in total

Review 1.  Etiology and significance of the optically clear nucleus.

Authors:  Zubair W Baloch; Virginia A LiVolsi
Journal:  Endocr Pathol       Date:  2002       Impact factor: 3.943

2.  Hürthle cell carcinoma in an autonomous thyroid nodule in an adolescent.

Authors:  A R Siddiqui; S Karanauskas
Journal:  Pediatr Radiol       Date:  1995

3.  Nuclear DNA analysis and prognosis in carcinoma of the thyroid gland. A nationwide study in Iceland on carcinomas diagnosed 1955-1990.

Authors:  J G Jónasson; J Hrafnkelsson
Journal:  Virchows Arch       Date:  1994       Impact factor: 4.064

4.  [Malignant thyroid neoplasms: a diagnostic challenge for ENT specialists].

Authors:  K Fruth; W J Mann
Journal:  HNO       Date:  2009-03       Impact factor: 1.284

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.